So, I’m a oncology scientist. I’ve been really focused on studying metastasized kidney cancer and all available treatments for it. Oh, I’ve come across this really cool therapy known as sorafenib. It’s a Precision Medicine that’s showing great promise for treating this aggressive cancer.

Targeted Therapy

Precision Medicine is this new type of cancer therapy thing that targets the particular molecules that initiate cancer growth and metastasize. Well, unlike traditional chemotherapytherapy that can really destroy both cancer and good cells, Precision Medicine tries to affect specifically the malignant cells and preserve normal cells.

Sorafenib is this poly-TKI inhibitor. It works by shutting down those enzymes that are highly critical for malignant cells to grow and live. This precision approach is far superior and not as unpleasant as the conventional chemotherapytherapy. It’s been indicating more efficient.

Metastatic Renal Cell Cancer

Late-stage Renal Cell Cancer is that stage IV cancer that’s like, ‘Intended to spread to various organs such as the lungs, bones, liver, etc. . ‘ This type of cancer is a major hassle to treat because it usually shows up very late. The aggressive nature of this cancer really pushes us to discover therapies that can decelerate and improve the quality of life for patients.

Sorafenib as a Treatment Option

Sorafenib got the green light from the U. S. Food and Drug Administration to treat progressive renal cell cancer, including metastatic ones. My research is showing that sorafenib is doing a great job at extending those progression-free and overall survival for people with Late-stage Renal Cell Cancer. This is really cool because it gives us an non-chemotherapy option, which can be a major discomfort for patients to deal with.

Challenges and Future Directions

Sorafenib appears promising, but don’t anticipate it as a healing solution for this metastatic kidney cancer issue. But we still got challenges, like patients developing resistance to the drug over time. Currently, I’m into identifying new objectives and combined treatments to make sorafenib even better and promote longer survival with this invasive cancer.

If you want to explore this topic further, here are some good reads for you:

• Choueiri, Thomas K.

  , et al. (2018). Targeted therapy for renal cell carcinoma. Nature Review of Clinical Oncology, volume 15, issue 1(1), 1-14.

• Escudier, B. , et al. (2011). Sorafenib for treatment of renal cell cancer: final efficacy and safety results of the third phase treatment, evaluation of effectiveness and length of response (TE2) trial. Journal of Clinical Oncology, volume 29, issue 31(31), 4210-4218.
• Bonessi, S. A. , et al. (2017). Sorafenib in renal cell carcinoma: a systematic review and meta-analysis of randomized controlled studies. Cancer Treatment Reviews, issue 60, 1-11.